← Back to headlines
FDA Review Meeting Scheduled for Compass Pathways' Depression Drug COMP360
An upcoming FDA review meeting will determine the future of Compass Pathways' depression drug candidate COMP360, as the company awaits regulatory feedback on its potential treatment.
25 Mar, 18:10 — 25 Mar, 18:10
Sources
Showing 1 of 1 sources
